esketamine has been researched along with Depression, Involutional in 88 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (6.82) | 24.3611 |
| 2020's | 82 (93.18) | 2.80 |
| Authors | Studies |
|---|---|
| Das, J | 1 |
| Nikayin, S; Sanacora, G | 1 |
| Buoli, M; Caldiroli, A; Capellazzi, M; Capuzzi, E; Clerici, M; Colmegna, F; Dakanalis, A; Marcatili, M; Tagliabue, I | 1 |
| Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A | 1 |
| Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G | 1 |
| Kasper, S; Lanzenberger, R; Naderi-Heiden, A; Praschak-Rieder, N; Unterholzner, J; Vanicek, T | 1 |
| Joshi, K; Le, HH; Li, S; Sheehan, JJ; Toro-Diaz, H; Voelker, J | 1 |
| Liu, D; Wang, H; Wang, Z; Wu, B; Yan, F; You, Y; Yuan, S; Zhang, F; Zhu, R; Zhu, X | 1 |
| Bouju, S; Codet, MA; Gaudré-Wattinne, E; Mekaoui, L; Rothärmel, M; Samalin, L; Sauvaget, A | 1 |
| Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza, LS; Souza-Marques, B; Vieira, F | 1 |
| Abdulahad, S; Aluisio, L; Bosma, ER; de Vries, E; Dijkstra, FM; Hartog, M; Huls, H; Jacobs, GE; Kuijper, DC; Singh, J; Solanki, B; Stuurman, FE; van de Loo, AJ; Verster, JC; Zannikos, P | 1 |
| Courtet, P; Lengvenyte, A; Olié, E; Strumila, R | 1 |
| Bahji, A; Vazquez, GH; Zarate, CA | 2 |
| Alnafeesi, Y; Ceban, F; Di Vincenzo, JD; Gillissie, ES; Jaberi, S; Jawad, MY; Lui, LMW; McIntyre, RS; Rosenblat, JD | 1 |
| Honyashiki, M; Inoue, T; Terao, I | 1 |
| Orsolini, L; Salvi, V; Volpe, U | 1 |
| Aan Het Rot, M; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Veraart, JK; Vischjager, M | 1 |
| Kobayashi, H; Ohnishi, T; Wakamatsu, A | 1 |
| Gu, T; Jiang, G; Liu, Q; Liu, S; Wang, Y; Yin, A; Zhang, L | 1 |
| Alves-Pereira, R; Bandeira, ID; Cardoso, TA; Faria-Guimarães, D; Fontes, M; Kapczinski, F; Lacerda, ALT; Leal, GC; Mello, RP; Quarantini, LC; Sampaio, AS; Silva, SS; Souza, LS; Souza-Marques, B; Vieira, F | 1 |
| Abdo, GL; Barbosa, MG; de Oliveira Cerqueira, R; Del Porto, JA; Del Sant, LC; Delfino, RS; Fava, VAR; Grossi, JD; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA | 1 |
| Daly, EJ; Gogate, JP; Kern Sliwa, JK; Manera, LS; Preskorn, SH; Starr, HL; Williamson, DJ; Winokur, A | 1 |
| Joshi, K; Karkare, S; Lefebvre, P; Morrison, L; Nash, AI; Pilon, D; Shah, A; Zhdanava, M | 1 |
| du Jardin, K; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G | 1 |
| Cubała, WJ; Wilkowska, A | 1 |
| Del Porto, JA; Delfino, RS; Grossi, JD; Lacerda, ALT; Surjan, J | 1 |
| Chao, Z; Fu, L; Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; Zhang, F; Zhou, Y | 1 |
| Fava, M; Feeney, A; Hock, RS; Iosifescu, DV; Iovieno, N; Jha, MK; Mathew, SJ; Murrough, JW; Papakostas, GI | 1 |
| Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G | 1 |
| Comparelli, A; Erbuto, D; Manfredi, G; Pompili, M; Sarli, G | 1 |
| Armeni, P; Costa, F; Falivena, C; Rognoni, C | 1 |
| Hashimoto, K | 2 |
| Harding, L; Joshi, K; Liberman, J; Pesa, J; Rui, P | 1 |
| d'Andrea, G; Lorenzo, GD; Mancusi, G; Martinotti, G; McIntyre, RS; Pettorruso, M | 1 |
| Cook, J; Halaris, A | 1 |
| Borentain, S; Daly, E; Macaluso, M; Nelson, JC; Salvadore, G; Sheehan, JJ; Singh, J; Trivedi, MH; Turkoz, I; Wilkinson, ST; Williamson, D | 1 |
| Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A | 1 |
| Chen, LN; Doherty, T; Drevets, WC; Fu, DJ; Lane, R; Morrison, RL; Popova, V; Sanacora, G; Wilkinson, ST; Zaki, N | 1 |
| Bernardo, WM; Floriano, I; Silvinato, A | 1 |
| Canuso, CM; Fu, DJ; Ionescu, DF; Jamieson, C; Lane, R; Molero, P; Qiu, X; Rozjabek, H | 1 |
| Bismark, A; Colvonen, P; Hunt, C; Lee, E; Nokes, B; Park, J; Ramanathan, D; Titone, MK | 1 |
| Anjo, J; Borentain, S; Canuso, CM; Fu, DJ; Guo, S; Mathews, M; Nash, AI; O'Hara, M; Shi, L; Zhang, Q | 1 |
| Bitsch, F; Falkenberg, I; Kircher, T; Liu, W; Matsingos, A; Noor, L; Vogelbacher, C; Yildiz, C | 1 |
| Deng, Q; Hu, Y; Li, A; Liu, J; Wang, G; Wang, H; Xiao, C; Zhang, L; Zheng, Y; Zhou, J; Zhu, X | 1 |
| Fu, DJ; Hong, JP; Ju, PC; Li, CT; Madriaga, G; Malek, AZA; Paik, JW; Siggins, S; Sulaiman, AH; Zhuo, J | 1 |
| Galán-Armenteros, RM; González-González, C; Marco-Feced, MA; Moreno-Campos, AJ; Romero-Mohedano, MC | 1 |
| Black, W; Bognar, A; Callander, JS; Dagge, D; Gitau, T; Hua, B; Joks, G; King, J; Liu, D; Lord, A; Scott, EM; Thornton, NLR; Ting, S | 1 |
| Corlett, PR; Hershenberg, R; Joormann, J; Kitay, BM; Macaluso, M; Martinez-Kaigi, V; Murphy, E; Nikayin, S; Rhee, TG; Sanacora, G; Shelton, RC; Thase, ME; Wilkinson, ST | 1 |
| Bauer, M; Findeis, H; Ritter, P | 1 |
| Kawalec, P; Kryst, J; Pilc, A | 1 |
| Aan Het Rot, M; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; van Asselt, ADI; Veraart, JKE | 1 |
| Bartoli, F; Wlkinson, ST | 1 |
| Cai, DB; Huang, X; Huang, XX; Jiang, WL; Ning, YP; Sim, K; Ungvari, GS; Xiang, YQ; Xiang, YT; Zheng, W | 1 |
| De Berardis, D; Di Giannantonio, M; Fornaro, M; Fraticelli, S; Kim, YK; Martinotti, G; Orsolini, L; Perna, G; Pompili, M; Serafini, G; Tomasetti, C; Valchera, A; Vellante, F; Volpe, U | 1 |
| Bolaños-Guzmán, CA; Gnecco, T; Parise, EM; Parise, LF; Sial, OK | 1 |
| Al Shweiki, MR; Barschke, P; Dorner-Ciossek, C; Hengerer, B; Oeckl, P; Otto, M; Pryce, C; Schönfeldt-Lecuona, C; Steinacker, P | 1 |
| Aluisio, L; Borentain, S; Daly, E; DiBernardo, A; Janik, A; Nijs, M; Singh, JB; Turkoz, I; Wajs, E; Wiegand, F | 1 |
| Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Lane, R; Li, X; Lim, P; Manji, H; Sanacora, G | 1 |
| David, S | 1 |
| Fava, M; Hock, RS; Iosifescu, DV; Jha, MK; Mathew, SJ; Murrough, JW; Papakostas, GI; Salloum, NC | 1 |
| Borissova, A; Curran, HV; Grabski, M; Marsh, B; Morgan, CJA | 1 |
| Bartova, L; Dold, M; Kasper, S | 1 |
| Ning, YP; Sim, K; Xiang, YT; Zheng, W | 1 |
| Drevets, WC; Li, QS; Ochs-Ross, R; Singh, J; Wajs, E | 1 |
| Chakravarty, S; K V, A; Mohan, AS | 1 |
| Brennan, E; Liebowitz, MR; Moran, M; Patel, A; Pereira, S; Wallier, J | 1 |
| Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Kasper, S; Lane, R; Lim, P; Manji, H; Qiu, X | 1 |
| Courtet, P; Nobile, B; Olié, E | 1 |
| Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH | 1 |
| Blackowicz, M; Cooper, K; Drevets, WC; Fedgchin, M; Floden, L; Hudgens, S; Jamieson, C; Lane, R; Popova, V; Singh, J | 1 |
| Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J | 1 |
| Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA | 1 |
| Borentain, S; Canuso, CM; Cepeda, MS; Daly, EJ; Drevets, WC; Lane, R; Manji, HK; Mathews, M; Popova, V | 1 |
| Brula, AQ; Sanders, B | 1 |
| Fietz, J; Kopf-Beck, J | 1 |
| Berk, M; Brietzke, E; Dodd, S; Gorwood, P; Ho, R; Iosifescu, DV; Kasper, S; Kratiuk, K; Lee, JG; Lee, Y; Lopez Jaramillo, C; Lui, LMW; Mansur, RB; McIntyre, RS; Murrough, JW; Nemeroff, CB; Papakostas, GI; Rosenblat, JD; Sanacora, G; Stahl, S; Subramaniapillai, M; Thase, M; Vieta, E; Young, AH; Zarate, CA | 1 |
| Brietzke, E; Di Vincenzo, JD; Gill, H; Ho, R; Lui, LMW; McIntyre, RS; Ng, J; Rodrigues, NB; Rosenblat, JD; Siegel, AN; Teopiz, KM | 1 |
| Ekstrand, J | 1 |
| Bahji, A; Baldessarini, RJ; Tondo, L; Undurraga, J; Vázquez, GH | 1 |
| Bauer, M; Findeis, H; Ludwig, VM; Ritter, P; Rucker, J; Sauer, C; Young, AH | 1 |
| Cooper, K; Daly, EJ; Drevets, WC; Fedgchin, M; Lim, P; Manji, H; Shelton, RC; Singh, JB; Thase, ME; Van Nueten, L; Winokur, A | 1 |
| Alphs, L; Canuso, CM; Drevets, WC; Fedgchin, M; Hough, D; Lane, R; Lim, P; Manji, H; Pinter, C; Sanacora, G; Singh, JB | 1 |
| Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E | 1 |
| Bitter, I; Blier, P; Cubala, WJ; Daly, EJ; Divacka, I; Drevets, WC; Duca, AR; Fagiolini, A; Hough, D; Janik, A; Lane, R; Li, H; Li, X; Lim, P; Manji, H; Molero, P; Shelton, RC; Singh, JB; Thase, ME; Trivedi, MH; Winokur, A; Zajecka, J; Zhang, Y | 1 |
30 review(s) available for esketamine and Depression, Involutional
| Article | Year |
|---|---|
Repurposing of Drugs-The Ketamine Story.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Drug Repositioning; Humans; Ketamine; Nerve Net; Receptors, N-Methyl-D-Aspartate | 2020 |
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Disease Management; Humans; Ketamine; Risk Assessment; Suicidal Ideation | 2021 |
Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Secondary Prevention | 2021 |
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2022 |
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Craving and addictive potential of esketamine as side effects?
Topics: Adult; Bupropion; Craving; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ketamine | 2022 |
The antidepressant effect and safety of non-intranasal esketamine: A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Randomized Controlled Trials as Topic | 2022 |
Arketamine for cognitive impairment in psychiatric disorders.
Topics: Animals; Antidepressive Agents; Cognitive Dysfunction; Depressive Disorder, Major; Ketamine; Mice | 2023 |
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2023 |
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Topics: Adult; Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Patient Reported Outcome Measures; Quality of Life; Randomized Controlled Trials as Topic; Suicidal Ideation | 2023 |
Ketamine in the Treatment of Depressive Episodes.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine | 2020 |
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic | 2020 |
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Clinical Trials as Topic; Databases, Factual; Depression; Depressive Disorder, Major; Drug Compounding; Glutamic Acid; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Suicide Prevention; Synaptic Transmission; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2020 |
Ketamine: The final frontier or another depressing end?
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamine Plasma Membrane Transport Proteins; Excitatory Amino Acid Antagonists; Humans; Ketamine; Norepinephrine Plasma Membrane Transport Proteins; Receptor, Muscarinic M1; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Receptors, Serotonin, 5-HT3; Receptors, sigma; Serotonin Plasma Membrane Transport Proteins | 2020 |
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Treatment Outcome | 2020 |
Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Mental Disorders; Mental Health; Middle Aged; Psychotropic Drugs; Substance-Related Disorders; Treatment Outcome | 2020 |
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
Topics: Administration, Intranasal; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Nasal Sprays; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Rapid acting antidepressants in the mTOR pathway: Current evidence.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Routes; Humans; Ketamine; Scopolamine; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases | 2020 |
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine | 2021 |
Esketamine for treatment-resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Middle Aged | 2020 |
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2021 |
Intranasal esketamine: From origins to future implications in treatment-resistant depression.
Topics: Administration, Intranasal; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Excitatory Amino Acid Antagonists; Humans; Hypertension; Implementation Science; Ketamine; Lower Urinary Tract Symptoms; Monitoring, Physiologic; Patient Selection; Personnel Staffing and Scheduling; Psychoses, Substance-Induced; Substance-Related Disorders; Suicidal Ideation | 2021 |
Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Retrospective Studies; Suicidal Ideation; Suicide | 2021 |
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Ketamine; Lithium Compounds; Randomized Controlled Trials as Topic | 2021 |
Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; History, 20th Century; History, 21st Century; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate | 2019 |
20 trial(s) available for esketamine and Depression, Involutional
| Article | Year |
|---|---|
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Japan; Ketamine; Prospective Studies; Treatment Outcome | 2021 |
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Topics: Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Treatment Outcome | 2022 |
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.
Topics: Antidepressive Agents; Automobile Driving; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Psychomotor Performance; Single-Blind Method | 2022 |
Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Factor Analysis, Statistical; Humans; Ketamine; Placebo Effect; Treatment Outcome | 2022 |
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.
Topics: Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Suicidal Ideation; Suicide | 2022 |
Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Treatment Outcome | 2023 |
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Quality of Life; Treatment Outcome | 2023 |
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Suicidal Ideation; Suicide; Treatment Outcome | 2023 |
The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Magnetic Resonance Imaging; Treatment Outcome | 2023 |
Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Midazolam; Pilot Projects | 2023 |
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.
Topics: Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Suicidal Ideation | 2023 |
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
Topics: Administration, Oral; Adult; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Treatment Outcome | 2019 |
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Patient Compliance; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2020 |
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Topics: Administration, Intranasal; Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Suicidal Ideation; Young Adult | 2020 |
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Topics: Administration, Intranasal; Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Outcome Assessment, Health Care; Patient Acuity; Suicidal Ideation; Young Adult | 2021 |
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Patient Health Questionnaire; Treatment Outcome | 2021 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ketamine; Male; Middle Aged; Treatment Outcome; Young Adult | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Ketamine; Male; Psychiatric Status Rating Scales; Risk Factors; Suicide Prevention | 2018 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Outcome Assessment, Health Care; Remission Induction; Secondary Prevention | 2019 |
38 other study(ies) available for esketamine and Depression, Involutional
| Article | Year |
|---|---|
Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Middle Aged | 2022 |
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder.
Topics: Antidepressive Agents; Borderline Personality Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Impulsive Behavior; Ketamine; Suicidal Ideation | 2022 |
US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior.
Topics: Administration, Intranasal; Adult; Depressive Disorder, Major; Health Care Costs; Humans; Ketamine; Nasal Sprays; Suicidal Ideation | 2022 |
S-Ketamine Exerts Antidepressant Effects by Regulating Rac1 GTPase Mediated Synaptic Plasticity in the Hippocampus of Stressed Rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; GTP Phosphohydrolases; Hippocampus; Ketamine; Neuronal Plasticity; rac1 GTP-Binding Protein; Rats; Stress, Psychological | 2023 |
Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
Topics: Administration, Intranasal; Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Nasal Sprays | 2022 |
A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (
Topics: Antidepressive Agents; Antipsychotic Agents; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Ketamine; Lithium; Psychopharmacology | 2022 |
Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic.
Topics: Animals; Antidepressive Agents; Autophagy; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Depressive Disorder, Major; Ketamine; Lipopolysaccharides; Mice; TOR Serine-Threonine Kinases | 2022 |
Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
Topics: Administration, Intranasal; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dizziness; Humans; Ketamine; Nasal Sprays; Nausea; Vertigo | 2022 |
Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Nasal Sprays; United States | 2022 |
Single dose S-ketamine rescues transcriptional dysregulation of Mtor and Nrp2 in the prefrontal cortex of FSL rats 1 hour but not 14 days post dosing.
Topics: Animals; Depression; Depressive Disorder, Major; Disease Models, Animal; Prefrontal Cortex; Rats; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2022 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Multicenter Studies as Topic; Observational Studies as Topic; Prospective Studies; Treatment Outcome | 2022 |
Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Middle Aged | 2023 |
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy.
Topics: Antidepressive Agents; Cost-Benefit Analysis; Depression; Depressive Disorder, Major; Humans; Nasal Sprays; Quality-Adjusted Life Years; Reproducibility of Results; Serotonin and Noradrenaline Reuptake Inhibitors | 2023 |
Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder.
Topics: Adult; Depressive Disorder, Major; Humans; Nasal Sprays; Retrospective Studies; Social Determinants of Health | 2023 |
The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Inflammation; Ketamine | 2023 |
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Comorbidity; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Retrospective Studies; Substance-Related Disorders | 2023 |
The effect of obstructive sleep apnea severity on PTSD symptoms during the course of esketamine treatment: a retrospective clinical study.
Topics: Depressive Disorder, Major; Humans; Polysomnography; Retrospective Studies; Sleep Apnea, Obstructive; Stress Disorders, Post-Traumatic; Veterans | 2023 |
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placeb
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Standard of Care; Suicidal Ideation; Treatment Outcome | 2023 |
A HOPEFUL ALTERNATIVE “THERAPY WITH INTRA- NASAL ESKETAMINE IN A PATIENT WITH RESISTANT DEPRESSION”. A CASE REPORT.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel.
Topics: Antidepressive Agents; Australia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Quality of Life | 2023 |
Ketamine and esketamine for suicidal ideation: Recent progress and practical issues.
Topics: Adult; Depressive Disorder, Major; Humans; Ketamine; Psychiatric Status Rating Scales; Suicidal Ideation | 2020 |
S-ketamine induces acute changes in the proteome of the mouse amygdala.
Topics: Amygdala; Animals; Depressive Disorder, Major; Ketamine; Mice; Proteome; Proteomics | 2020 |
Response to a recently published systematic review on intranasal esketamine for major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine | 2020 |
Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies - Authors' reply.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine | 2020 |
Genome-wide association study and polygenic risk score analysis of esketamine treatment response.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Genetic Markers; Genetic Predisposition to Disease; Genome-Wide Association Study; Genome, Human; Humans; Ketamine; Male; Middle Aged; Risk Factors | 2020 |
Managing dissociative symptoms following the use of esketamine nasal spray: a case report.
Topics: Administration, Intranasal; Depressive Disorder, Major; Dissociative Disorders; Female; Humans; Ketamine; Middle Aged; Nasal Sprays | 2021 |
A new indication for esketamine nasal spray (Spravato).
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Suicidal Ideation | 2020 |
The Antisuicidal Effect of Esketamine Should Be Further Investigated.
Topics: Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Suicidal Ideation | 2020 |
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays | 2021 |
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Retrospective Studies | 2021 |
Comments to Drs. Bahji, Vazquez, and Zarate.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Moving toward a process-oriented perspective in the personalized treatment of depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Precision Medicine | 2021 |
Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Topics: Administration, Intravenous; Adult; Aged; Antidepressive Agents; Blood Pressure; Cohort Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Interactions; Female; Heart Rate; Humans; Injections, Subcutaneous; Ketamine; Male; Middle Aged; Monoamine Oxidase Inhibitors; Retrospective Studies; Tranylcypromine; Young Adult | 2021 |